Brief: Lilly Expects Concord Site To Begin Production Of GlP-1 Drugs As Early As 2024-End

Catalent

06/02/2024 16:25

Feb 6 (Reuters) - Eli Lilly and Co  LLY.N :
    * LILLY EXEC SAYS EXPECT CONCORD NORTH CAROLINA SITE TO
BEGIN
PRODUCTION OF GLP-1 DRUGS AS EARLY AS THE END OF 2024 - CONF
CALL
    * LILLY EXEC EXPECTS PRODUCTION OF SELLABLE DOSES OF GLP-1
DRUGS
IN H2 2024 WILL BE AT LEAST ONE AND A HALF TIMES PRODUCTION IN
H2 2023
    * LILLY EXEC SAYS STUDY OF TIRZEPATIDE TO TREAT NASH WAS NOT
DESIGNED TO BE STATISTICALLY POWERED TO EVALUATE IMPROVEMENT IN
FIBROSIS
    * LILLY EXEC SAYS EXPECT TO TAKE AT LEAST FIVE NEW MOLECULES
INTO
THE CLINIC THIS YEAR
    * LILLY EXEC SAYS PLAN TO BUILD CAPACITY FOR ITS GLP-1 PILL
ORFORGLIPRON AHEAD OF PHASE 3 TRIAL
    * LILLY EXEC SAYS "INTEND ON HOLDING CATALENT ACCOUNTABLE TO
THEIR
CONTRACT" AS CO GAINS MORE INFORMATION ON NOVO-CATALENT DEAL
    * LILLY EXEC SAYS CO HAS PRODUCTS WITH CATALENT SITES, FOCUS
IS ON
ENSURING CONTINUITY OF SUPPLY IS UNINTERRUPTED


Further company coverage:  LLY.N 

 ((Reuters.Briefs@thomsonreuters.com;))